Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully-integrated specialty biopharmaceutical company, today announced the first patient dosed in its Phase 2a study of collagenase clostridium histolyticum (or "CCH") for the treatment of edematous fibrosclerotic panniculopathy ("EFP"), commonly known as cellulite. As previously reported, Phase 1b open label dose-ranging study results demonstrated that some doses of CCH provided potential improvement in the cellulite target dimple volume following a single injection into that dimple. The most common adverse events (>10%) in this study included injection site bruising and pain.